Dr Lal PathLabs reports Q3 revenue of Rs 660 crore, posts strong growth amid labour code impact
The company recorded consolidated revenue of Rs. 660 crore in Q3 FY26, up
The company recorded consolidated revenue of Rs. 660 crore in Q3 FY26, up
The Poultry Healthcare Division delivered a strong performance, posting 32% revenue growth in Q3 FY26 and 17% growth over the nine-month period
The Union Budget 2026–27 accords strong priority to the upgradation and expansion of healthcare infrastructure and medical education
A nationwide network of over 1,000 accredited clinical trial sites will be created to accelerate drug development timelines and enhance research credibility
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
CSPC will receive an upfront $1.2 billion from AstraZeneca for access to eight programmes, AI molecular design capabilities, and the LiquidGel platform
The facility will bring 850 high-value jobs to the region, including engineers, scientists, operations personnel, and lab technicians
The company’s total income jumped 31% year-on-year to Rs 125.5 crore
rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million
Subscribe To Our Newsletter & Stay Updated